However, patients should be screened for contraindications, such as a history of pancreatitis or certain gastrointestinal conditions
Blood sugar management, metabolic health, kidney health, heart risk, and medication alternatives are medical decisions
By 104 weeks, approximately 77% of SELECT patients on dose were receiving the target semaglutide 2.4 mg weekly dose, which is lower than the corresponding proportion of patients in STEP 1 (89.6% were receiving the target dose at week 68) 14,21
PaulyRPDemuthHURoscheFSchmidtJWhiteHALynnFet al
It is thought 2040% have drug-induced SCLE
GLP-1RAs are a novel class of glucose-lowering agents that mimic the physiological actions of endogenous GLP-1 by enhancing insulin secretion, reducing glucagon release, and acting on the brain to inhibit gastrointestinal motility, thereby slowing nutrient absorption